Preclinical News and Research

RSS

Patent claims allowed covering Samaritan's Alzheimer's memory recovery drug in Australia

Samaritan Pharmaceuticals, a biopharmaceutical company committed to commercializing new innovative therapeutic drugs, has received notification that the claims in the patent application for "Neuroprotective Spirostenol Pharmaceutical Compositions" covering Caprospinol (SP-233) have been allowed by the Australian Patent Office.

6 May 2008

Geron Corporation awarded UK grant funding for human embryonic stem cell research

Geron Corporation announced today two grant awards to the University of Edinburgh from the UK Stem Cell Foundation, with funding from the Medical Research Council and Scottish Enterprise.

6 May 2008

Prana Biotechnology has discovered novel drug candidates for use in Parkinson's disease

Prana Biotechnology Limited has announced that it has identified novel therapeutic drug candidates from its Parkinson's disease program. Already, a lead candidate drug has demonstrated positive effects in pre-clinical studies, protecting the brain from damage to the substantia nigra, the area of the brain affected in Parkinson's disease.

6 May 2008

Drug candidate to treat smallpox scaled up by new partnership

Two American companies are teaming up for second-round test-phase production of a FDA-designated "fast track" drug candidate to treat smallpox, a deadly virus that is feared to be able to reach people through acts of bio-warfare or bio-terrorism.

5 May 2008

Anti-HIV NanoViricide drug candidate shows promise in animal trials

NanoViricides, Inc said that its anti-HIV drug candidates demonstrated significant therapeutic efficacy in the recently completed preliminary animal studies.

5 May 2008

U-M receives grant to provide free and open, online health professions educational materials

The University of Michigan has launched an ambitious pilot project to make comprehensive pre-clinical health curricula available worldwide via the Internet.

1 May 2008

ImmunoVaccine Technologies patents DepoVax vaccine platform

ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, unveiled today its DepoVax platform, a novel depot vaccine delivery system used to increase the efficacy and strength of vaccines. IVT has filed additional patents to protect the DepoVax concept.

30 Apr 2008

Gene therapy restores vision in patients with rare congenital blindness

In a clinical trial at The Children's Hospital of Philadelphia, researchers from The University of Pennsylvania have used gene therapy to safely restore vision in three young adults with a rare form of congenital blindness.

27 Apr 2008

Biopharmaceutical spin-out company Domainex, secures funding

Headquartered in London, Domainex is a contract research company specialising in the provision of structural biology and chemistry services to major pharmaceutical and biotechnology firms. The Company is also developing a pipeline of pre-clinical drugs and targets.

From Domainex 23 Apr 2008

MacroChem acquires Virium Pharmaceuticals

MacroChem Corporation announced today that on April 18, 2008 it acquired Virium Pharmaceuticals Inc., a non-public, development stage company developing and commercializing novel therapeutics, with a portfolio of clinical stage product candidates focused in oncology, including its next generation nucleoside analogue licensed from the Southern Research Institute.

23 Apr 2008

Discovery of primary driver of tumor development in the stomach

In a discovery that could lead to the development of new treatments for gastric cancer, scientists at the Melbourne Branch of the international Ludwig Institute for Cancer Research (LICR) have discovered what appears to be the primary driver of tumor development in the stomach.

22 Apr 2008

New advance in use of oncolytic viruses as novel cancer treatments

Combining a herpes virus genetically altered to express a drug-enhancing enzyme with a chemotherapy drug effectively and safely reduced the size of highly malignant human sarcoma grafted into mice.

22 Apr 2008

Lorus initiates development program exploring novel route of administration for LOR-2040

Lorus Therapeutics Inc. today announced the start of a development program aimed at expanding the therapeutic application of its lead clinical-stage drug LOR-2040 for the treatment of superficial bladder cancer.

22 Apr 2008

MaxCyte introduces large scale transfection technology - accelerates cell-based assay development

MaxCyte has announced the introduction of its ITF Inline Transfection System, a validated platform for preparative transfection, based on unique flow electroporation technology.

21 Apr 2008

Raptor Pharmaceuticals initiates phase IIa clinical study for Convivia

Raptor Pharmaceuticals Corp. has announced that its clinical development subsidiary, Bennu Pharmaceuticals Inc. , has initiated the Company's first clinical-stage program after dosing the first cohort in a Phase IIa study of oral 4-methylpyrazole ("4-MP") in subjects with ALDH2 deficiency, or ethanol intolerance, as the initial development stage of its Convivia program.

21 Apr 2008

Aida Pharmaceuticals announces development of new anti-cancer drug

Aida Pharmaceuticals, Inc. has announced that it is developing a potential cancer drug that seeks to trigger cell death in certain types of cancer.

18 Apr 2008

New drug for melanoma riluzole shows promise

Rutgers Professor Suzie Chen has found that riluzole, a U.S. Food and Drug Administration (FDA) approved drug used to treat Lou Gehrig's disease (ALS), slows the growth of melanoma, the most aggressive form of malignant skin cancer.

16 Apr 2008

Drugs in the pipeline: new therapies that could change treatment strategies

The investigational drug AZD2171 (cediranib) may help shrink tumors and prolong survival of patients with a relatively common, aggressive type of brain cancer, according to results from a clinical trial conducted by Boston researchers.

16 Apr 2008

Restricted calorie diets prevent pancreatic inflammation and cancer

Prevention of weight gain with a restricted calorie diet sharply reduced the development of pancreatic lesions that lead to cancer in preclinical research reported today by researchers from The University of Texas at Austin and The University of Texas M. D. Anderson Cancer Center at the American Association for Cancer Research annual meeting.

16 Apr 2008